REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. (RGNX) on August 25, 2026. The filing reports corporate governance changes, specifically the election of a new director and the resignation of two existing directors, effective immediately.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation arrangements:
- Initial Equity Award (Gregory Ciongoli): Aggregate grant date fair value of $550,000.
- Equity Composition: 75% non-statutory stock options (exercise price $8.91/share) and 25% restricted stock units (RSUs).
- Annual Cash Retainer: $45,000 for Board service, plus $10,000 for the Audit Committee and $5,000 for the Nominating and Corporate Governance Committee.
Material Changes
The primary material change is the composition of the Board of Directors:
- New Director: Gregory Ciongoli was elected as a Class II director, with a term expiring at the 2029 annual meeting. He is designated as independent and appointed to the Audit and Nominating and Corporate Governance Committees.
- Resignations: Jean Bennett, M.D., Ph.D., and A.N. "Jerry" Karabelas, Ph.D., resigned from the Board effective August 25, 2026.
- Board Size: The Board size was reduced to nine directors.
- Transition: Resigning directors will serve as advisors to assist the Board until February 2027.
Outlook, Risks, and Unusual Items
The filing contains no management commentary on business outlook, risks, contingencies, or unusual items. It strictly addresses the governance transition and associated compensation terms. The equity awards include acceleration provisions in the event of a change of control or death.
Investor Verification Checklist
- Verify the independence status of the new director, Gregory Ciongoli, as declared by the Board.
- Confirm the vesting schedule details for the $550,000 equity award (3-year vesting with specific acceleration clauses).
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the board changes.
- Monitor future filings for the impact of the reduced board size on committee operations.